

SIRS and Sepsis in Cardiothoracic Surgery



REGAIN CONTROL

Your CytoSorb Therapy goals:

- Control excessive systemic inflammation
- Modulate the immune response
- Stabilize hemodynamics
- Prevent and limit organ dysfunctions



Stabilization of hemodynamics and organ functions

- Improvement of hemodynamic stability ⁽¹⁾
- Reduction of catecholamine need
- Modulation of the immune response ^(1, 3, 6)
- Prevention and limitation of inflammation induced organ injury ^(4,6,7)


Intra- and postoperative applications

- Intraoperative use to attenuate inflammatory activation in high risk patients on cardiopulmonary bypass (CPB): long CPB times, redo or combination procedures, endocarditis ⁽⁸⁾
- Postoperative use to regain control in severe SIRS or sepsis induced organ dysfunction ⁽⁶⁾

Unique extracorporeal therapy

- Safe and easy to use whole blood perfusion
- Easy to combine with CPB or routine renal replacement therapies (RRT) within minutes
- Quick and sustained reduction of excessive cytokine levels and free hemoglobin ⁽¹⁾
- Use of standard anticoagulation (heparin or citrate)
- Excellent hemo- and biocompatibility (fulfills ISO 10993)

Intelligent polymer technology



Literature:

1. Peng ZY et al. Crit Care Med. 2008 May;36(5):1573-7
2. Kellum JA et al. Crit Care Med. 2004 Mar;32(3):801-5
3. Namas RA et al. Mol Med. 2012 Dec 20;18:1366-74
4. Peng ZY et al. Kidney Int. 2012 Feb;81(4):363-9
5. Schaedler D et al. Abstract, Crit Care 2013, 17 (suppl 2): P62
6. Peng ZY et al. Crit Care. 2014 Jul 3;18(4):R141
7. Mikhova KM et al. J Thorac Cardiovasc Surg. 2013 Jan;145(1):215-24
8. Born F et al. Kardiotechnik 2014;2:41-46

